Sodium reduction
BehavioralTeaching and skill building to reduce dietary sodium
NCT Number: NCT01733017
The purpose of is to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 2
University of Kentucky, College of Nursing, Lexington, Kentucky, United States
For a majority of patients with advanced heart failure, medical treatment is only partially effective in relieving heart failure symptoms. Therefore, it is recommended that palliative care be initiated soon after diagnosis. There is a need for complementary, nonpharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Clinical trials to date have only tested each nutrient individually. There is strong theoretical rationale that a combined intervention targeting all three nutrients would have substantial benefit in relieving symptoms in advanced heart failure. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this placebo controlled study are 1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; 2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and 3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 150 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group (75 per group). The nutrition intervention group will receive a theory based education and skill building intervention designed to decrease dietary sodium intake to ~2 g per day. A research nurse will make 4 home visits and one follow-up telephone call over 6 months to provide the education-skill building intervention. The intervention group will take 3 omega-3 fatty acid capsules (350 mg eicosapentaenoic acid and 50 mg docosahexaenoic acid) and consume tomato juice or other tomato-based products containing 20-25 mg of lycopene daily for six months. The placebo group will receive the same number of visits and phone calls but only general nutrition information will be provided. They will take 3 placebo capsules containing rice oil (500 mg/capsule) and consume their choice of fruit juices that do not contain lycopene daily for six months. Data will be collected in person at baseline, 3 months, and 6 months by a research assistant blinded to the group assignment. Patients will be followed for an additional 6 months by telephone to collect longer term data on symptom burden and quality of life as well as heart failure hospitalization and all-cause mortality at 9 and 12 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Teaching and skill building to reduce dietary sodium
omega-3 fatty acid supplements and juices containing lycopene
placebo capsules
Other names: placebo
Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
Other names: attention control
Time frame: 12 months
Combined endpoint of cardiac-related hospitalization and all cause mortality
Time frame: baseline, 3, 6, 9, and 12 months
combined score of symptom severity, frequency, and distress for common symptoms of heart failure
Time frame: baseline, 3, 6, 9, 12 months
heart failure related quality of life
Time frame: baseline, 3, 6, 9, 12 months
the ratio of EPA plus DHA as a percentage of total fatty acids in the cell membrane of erythrocytes
Time frame: baseline, 3, 6, 9, 12 months
serum levels of malondialdehyde and 8-iso-PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen free radical production exceeding antioxidant capacity
Time frame: baseline, 3, 6, 9, 12 months
Serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors: sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity; interleukin-10 (IL-10) will be measured as a marker of anti-inflammatory cytokine activity
Time frame: baseline, 3, 6, 9, 12 months
Plasma lycopene will be measured as a marker intervention effectiveness
Time frame: baseline, 3, 6, 9, 12 months
Three 24-hour diet recall interviews at each timepoint will be used estimate sodium intake and to identify high sodium foods and eating patterns for the sodium reduction component of the intervention.
Terry Lennie
Other
Nutrition Intervention to Reduce Symptoms in Patients With Advanced Heart Failure
Acronym: NIHFT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05806606
Behavior, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06847438
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07721909
Cardiovascular Diseases, Heart Diseases
Muscat, Oman
View Trial Details